Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone and Bupropion SR Combination in Uncomplicated Obesity
NCT00364871Phase 2Completed
- Sponsor
- Orexigen Therapeutics
- Start
- Apr 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone and bupropion in obesity (7 arms), sponsored by Orexigen Therapeutics. Primary endpoint: Percentage change in total body weight at 24 weeks. Started Apr 2005; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00364871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00364871.